<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04221906</url>
  </required_header>
  <id_info>
    <org_study_id>BOS-475-102</org_study_id>
    <secondary_id>2019-002447-17</secondary_id>
    <nct_id>NCT04221906</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Safety and Antipsoriatic Efficacy of BOS-475 in a Psoriasis Plaque Test</brief_title>
  <official_title>A Phase Ib, Multi-Center, Randomized, Vehicle- and Comparator-Controlled Trial, Double-Blind for the Investigational Medicinal Products, Observer-Blind for the Comparators to Evaluate the Safety and Antipsoriatic Efficacy of BOS-475 in a Psoriasis Plaque Test</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boston Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boston Pharmaceuticals</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is being conducted to evaluate the safety of topical BOS-475 compared to topically&#xD;
      applied comparator formulations and vehicle.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a three-center, randomized, placebo- and comparator-controlled, double-blind for the&#xD;
      Investigational Medicinal Products (IMPs), observer-blind for the controls, intraindividual&#xD;
      comparison of all 6 treatments.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 6, 2020</start_date>
  <completion_date type="Actual">March 6, 2020</completion_date>
  <primary_completion_date type="Actual">March 6, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of treatment-emergent adverse events (TEAEs)</measure>
    <time_frame>up to Day 19</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of treatment-emergent application site reactions</measure>
    <time_frame>up to Day 19</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from Baseline in systolic and diastolic blood pressure</measure>
    <time_frame>Baseline; up to Day 19</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from Baseline in pulse</measure>
    <time_frame>Baseline; up to Day 19</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from Baseline in respiration</measure>
    <time_frame>Baseline; up to Day 19</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from Baseline in body temperature</measure>
    <time_frame>Baseline; up to Day 19</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with clinically significant physical examination findings</measure>
    <time_frame>up to Day 19</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in psoriatic infiltrate thickness on Day 19 (assessed by measurement of the thickness of the Echo Poor Band [EPB] of the inflammatory infiltrate using 22-megahertz (MHz) sonography)</measure>
    <time_frame>Baseline; Day 19</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in psoriatic infiltrate thickness on Days 8 and 15 (assessed by measurement of the thickness of the EPB of the inflammatory infiltrate using 22-MHz sonography)</measure>
    <time_frame>Baseline; Days 8 and 15</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the curve (AUC) of change from Baseline in thickness of the EPB of the inflammatory infiltrate</measure>
    <time_frame>Baseline; Day 19</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in the test fields compared to the surrounding plaque skin, as an evaluation of the antipsoriatic efficacy by clinical assessment, using a 5-point score</measure>
    <time_frame>Baseline; Days 1, 8, 15, and 19 (End of Trial)</time_frame>
    <description>-1 = worsened; 0 = unchanged (no effect); 1 = slight improvement; 2 = clear improvement but not completely healed; 3 = completely healed.</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Chronic Plaque Psoriasis</condition>
  <arm_group>
    <arm_group_label>BOS-475 0.5%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Daily application of BOS-475 0.5%</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BOS-475 1%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Daily application of BOS-475 1%</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BOS-475 2%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Daily application of BOS-475 2%</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Active ingredient-free vehicle cream</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Daily application of vehicle cream</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Daivonex cream</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Daily application of Daivonex cream (calcipotriol 0.005%)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Betnesol-V cream (betamethasone 0.1%)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Daily application of Betnesol-V cream (betamethasone 0.1%)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BOS-475</intervention_name>
    <description>topical cream</description>
    <arm_group_label>BOS-475 0.5%</arm_group_label>
    <arm_group_label>BOS-475 1%</arm_group_label>
    <arm_group_label>BOS-475 2%</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Active ingredient-free vehicle cream</intervention_name>
    <description>topical cream</description>
    <arm_group_label>Active ingredient-free vehicle cream</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Daivonex cream (calcipotriol 0.005%)</intervention_name>
    <description>topical cream</description>
    <arm_group_label>Daivonex cream</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Betnesol-V cream (betamethasone 0.1%)</intervention_name>
    <description>topical cream</description>
    <arm_group_label>Betnesol-V cream (betamethasone 0.1%)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Men, or women of non-childbearing potential aged 18-69 years (inclusive)&#xD;
&#xD;
          -  Participants with chronic stable plaque psoriasis&#xD;
&#xD;
          -  The target lesion(s) should be on the trunk or extremities (excluding palms/soles);&#xD;
             psoriatic lesions on the knees or elbows are not to be used as target lesions.&#xD;
&#xD;
          -  Willing and able to follow all trial procedures and complete the whole trial&#xD;
&#xD;
          -  Capable of giving signed informed consent which includes compliance with the&#xD;
             requirements and restrictions listed in the Informed Consent Form (ICF) and in this&#xD;
             protocol&#xD;
&#xD;
          -  Willing to refrain from using any topical treatments on the target areas, other than&#xD;
             those mandated by the protocol or for protocol procedures&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Other skin disease or infection that is considered by the investigator to be relevant&#xD;
             to the outcome of the trial&#xD;
&#xD;
          -  Participants with acute psoriasis guttata, psoriasis punctata, psoriasis&#xD;
             erythrodermatica or pustular psoriasis&#xD;
&#xD;
          -  Any topical antipsoriatics on plaques potentially to be treated in this trial&#xD;
             (including corticosteroids, vitamin D analogues, immunomodulators, retinoids,&#xD;
             dithranol and tar) in the 4 weeks before first treatment and/or during the trial&#xD;
             (pretreatment with salicylic acid is permitted on selected plaques; treatment on the&#xD;
             face, ears and scalp is also permitted as lesions are not involved in the trial)&#xD;
&#xD;
          -  Systemic treatment with antipsoriatics, e.g., corticosteroids, cytostatics, retinoids,&#xD;
             dimethylfumarate or apremilast in the three months before first treatment and during&#xD;
             the trial&#xD;
&#xD;
          -  Systemic treatment with biological treatments: ustekinumab or secukinumab within six&#xD;
             months or adalimumab, infliximab, and etanercept within three months before first&#xD;
             treatment and during the trial. Any other previously used biologics for treatment of&#xD;
             psoriasis should have been washed out for five half lives before first treatment.&#xD;
&#xD;
          -  Ultraviolet A (UVA) or B-therapy within four weeks and psoralen and ultraviolet A&#xD;
             (PUVA)-therapy within eight weeks before first treatment and during the trial&#xD;
             treatment with concomitant medication that may affect and provoke or aggravate&#xD;
             psoriasis, e.g., antimalarial drugs, lithium, beta-blockers, or&#xD;
             angiotensin-converting-enzyme (ACE) inhibitors unless on a stable dose for 3 months&#xD;
             before trial medication initiation&#xD;
&#xD;
          -  History of malignancy within 5 years prior to dosing, except adequately treated&#xD;
             non-invasive skin cancer (basal or squamous cell carcinoma&#xD;
&#xD;
          -  Positive urine drug or breath alcohol test results during screening or at Day 1, or&#xD;
             history of drug abuse within a year prior to the screening visit&#xD;
&#xD;
          -  Excess alcohol consumption within 6 months prior to the trial defined as an average&#xD;
             weekly intake of &gt; 14 units for males and females. One unit is equivalent to 8 grams&#xD;
             of alcohol: a half-pint (~240 milliliters [mL]) of beer, 1 glass (125 mL) of wine, or&#xD;
             1 (25 mL) measure of spirits&#xD;
&#xD;
          -  Blood pressure (BP) &gt;160 millimeters of mercury (mmHg) systolic or &gt;95 mmHg diastolic&#xD;
             at screening&#xD;
&#xD;
          -  Participation in another clinical trial within the last six months for biological&#xD;
             agents, or four weeks for small molecules prior to first treatment in this clinical&#xD;
             trial&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>69 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xiaobing Qian, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Boston Pharmaceuticals, Vice President, Clinical Development</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Gemeinschaftspraxis Dr. med. Johannes Niesmann und Dr. med. Nick Othlinghaus Hauszentrum im Jahrhunderthaus - Zentrum f√ºr klinische Studien</name>
      <address>
        <city>Bochum</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>bioskin GmbH</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinische Forschung Schwerin GmbH</name>
      <address>
        <city>Schwerin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>January 7, 2020</study_first_submitted>
  <study_first_submitted_qc>January 7, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 9, 2020</study_first_posted>
  <last_update_submitted>November 17, 2020</last_update_submitted>
  <last_update_submitted_qc>November 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>BOS-475</keyword>
  <keyword>antipsoriatic efficacy</keyword>
  <keyword>safety</keyword>
  <keyword>psoriasis plaque test</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Betamethasone</mesh_term>
    <mesh_term>Calcipotriene</mesh_term>
    <mesh_term>Betamethasone sodium phosphate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

